A Los Angeles biotech startup hoping to launch the next big drug or medical device might have gone broke trying to open a research laboratory as recently as the turn of the century.
Not so these days – fledgling firms in the region now can rent lab space at a growing number of life science incubators, which can cut costs and help draw millions of dollars in support for promising drugs and medical devices.
The region’s incubators were showcased April 5 at a UCLA conference in support of startup companies, and deemed vital by bioscience proponents to the industry’s growing presence in Los Angeles County.
“Believe it or not, fifteen years ago, we didn’t have any life science incubators,” said Ahmed Enany, chief executive of the Southern California Biomedical Council, a Los Angeles-based trade group that hosted the conference at UCLA’s California NanoSystems Institute. “Now we have nine.”
The conference drew more than 100 early stage biomedical entrepreneurs seeking incubator space, investor funding and guidance on how to build a successful company.
The function of such incubators is simple: to provide affordable research and development space within a laboratory equipped with benches, equipment and needed hookups for gas, waste and other features.
Such shared research and development facilities, available for lease at between $20 and $30 a square foot, can also connect entrepreneurs to a wealth of scientific support from nearby research institutions, from UCLA to Caltech to Cal Poly Pomona.
The bulk of the 100 or so biotech firms headquartered in Los Angeles County are in the early stage, Enany said, with about half residing at incubators.
Recent breakthroughs – and deals – include: a stem-cell gene therapy developed inside Alexandria Innovation Center in Pasadena that led to last year’s $91 million acquisition of Calimmune Inc. by CSL Behring; molecular imaging for cancer immunotherapies developed at Momentum Biosciences in Culver City, which precipitated a $47 million investment rounds for ImaginAb Inc. of Inglewood; and several biomedical advances from pharmaceuticals to diagnostics to medical devices hatched at the Pasadena Bio Collaborative Incubator, which have drawn millions of dollars in support for dozens of bioscience firms.
The Pasadena incubator, the region’s first to open, now hosts 22 biotech, diagnostic and medical device companies within 12,000 square feet of refurbished space.
It has graduated 17 successful companies since 2004, including Auritec Pharmaceuticals Inc. and Neumedicines Inc., of Pasadena, PLC Diagnostics Inc. of Thousand Oaks, iNDX Lifecare Inc. of Los Gatos and ChromoLogic of Monrovia.
“We don’t vet people for their science,” said Robert “Bud” Bishop, chief executive for Pasadena Bio, told the conference. “They can rent month-to-month. We can set up a company in as little as two days.”
Other incubators in Los Angeles and eastern Ventura counties include Alexandria; Momentum; Magnify, located at UCLA’s California NanoSystems Institute (CNSI); CTTi at Cal Poly Pomona; Lab Launch in Monrovia; LA BioMed in Torrance; BATTS Labs in Northridge and Ventura BioCenter in Thousand Oaks.
The combined incubator spaces host more than 55 companies in 70,000 square feet of mixed office and wet lab space.
The 21 life and physical science companies at UCLA’s Magnify incubator have raised $115 million in funding since 2014. Companies that have come through the incubator’s doors have developed everything from drugs to lessen scars and promote wound healing to 3-D printed batteries.
“We’re not just a UCLA incubator – we’re an L.A. incubator,” said Brian Benson, director of entrepreneurship and commercialization at the nanotech institute. “CNSI’s almost 200,000 square feet building acts as a lightning rod for innovation.”
New incubator labs worth a combined $110 million are expected to open within the coming year at LA BioMed and Cal State Los Angeles, along with Hatch BioScience Labs in El Sereno.
Sofie Biosciences Inc., a Culver City-based molecular imaging diagnostics company, was launched in 2008 out of Momentum Biosciences, the incubator founded by UCLA and Caltech faculty to create a home for entrepreneurs who might have otherwise set up shop in biotech hubs in the Bay Area, San Diego or Boston.
Sofie acquired last fall Zevacor Pharma Inc., a positron emission tomography—or PET scan – radiopharmaceutical company based in Virginia, for an undisclosed sum.
The company, which had raised more than $12 million in venture capital through 2016, just closed on a $16 million Series B round, executives said. Investors include former Los Angeles Mayor Richard Riordan.
“For us, the UCLA faculty owners and founders were huge,” said Sofie’s Chief Executive Patrick Phelps – whose father, Sofie Chairman Dr. Michael Phelps, invented the PET scanner. “They gave us a very strong vision and expertise that we could never have been able to afford.”
Staff reporter Dana Bartholomew can be reached at firstname.lastname@example.org or (323) 556-8333.
For reprint and licensing requests for this article, CLICK HERE.